GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company focused on diseases of the central nervous system. Its stock price is primarily dependent on the commercial success of its drugs and the clinical trial results of new candidates in its pipeline.
Share prices of companies in the market segment - Neuro
ACADIA is a biopharmaceutical company focused on treating diseases of the central nervous system. We classify it as part of the Neuro sector, and the chart below shows the dynamics of this segment as a whole, reflecting trends in this field of medicine.
Broad Market Index - GURU.Markets
ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. As a component of the GURU.Markets index, it reflects the hopes and risks of the biotech sector. The chart below represents the entire market. Compare ACADIA's performance to the overall trend to understand sentiment in the neuroscience sector.
Change in the price of a company, segment, and market as a whole per day
ACAD - Daily change in the company's share price ACADIA Pharmaceuticals
The volatility of ACADIA Pharmaceuticals, which focuses on CNS diseases, reflects the high risks of the biotech sector. Change_co is the immediate market reaction to clinical trial results. This metric is indispensable for building risk models for innovative pharmaceutical companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
ACADIA Pharmaceuticals Inc. is a biotech company. This chart highlights the sector's high volatility. Comparing it to ACAD, which focuses on CNS diseases, helps assess its risk relative to more diversified pharmaceutical companies.
Daily change in the price of a broad market stock, index - GURU.Markets
ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of diseases of the central nervous system. Neuroscience is a risky area of research. The chart below illustrates the high volatility typical of the biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ACADIA Pharmaceuticals
ACADIA is a biotech company specializing in the treatment of diseases of the central nervous system. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform.
Annual dynamics of market capitalization of the market segment - Neuro
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on treating diseases of the central nervous system. Its success depends on the commercialization of its key drugs and R&D results. The chart below shows how the market views its scientific potential and the competitive landscape in neuroscience.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ACADIA Pharmaceuticals is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ACADIA Pharmaceuticals
ACADIA Pharmaceuticals's value depends on the success of its neuroscience drugs. The monthly fluctuations on the chart reflect sales data for its Parkinson's disease psychosis medications, as well as news about clinical trials of new drugs, which are crucial for its long-term growth.
Monthly dynamics of market capitalization of the market segment - Neuro
ACADIA Pharmaceuticals specializes in developing drugs to treat central nervous system disorders, such as psychosis associated with Parkinson's disease. This is a complex and risky area of pharmacology. The chart below reflects general trends in the neuroscience development sector, including investor attitudes toward long-term research.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks, especially in complex fields like neuroscience, often take on a life of their own, reacting to trial news. The chart below shows general market trends. Is ACADIA Pharmaceuticals following this trend, or are its commercial successes and R&D developments creating a unique story?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ACADIA Pharmaceuticals
Shares of ACADIA Pharmaceuticals, which focuses on CNS diseases, follow the rhythm of biotech news. Their weekly price movements are a direct response to clinical trial results, FDA decisions, and news about potential competitors, reflecting the high risks and investor expectations.
Weekly dynamics of market capitalization of the market segment - Neuro
Neuroscience-focused biotech companies like ACADIA often move together, driven by shared news of breakthroughs or setbacks in brain disease treatments. The chart below illustrates this general sentiment across the niche. It allows one to gauge the market's confidence in ACADIA's drugs compared to those of its competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ACADIA Pharmaceuticals specializes in diseases of the central nervous system. Like many biotech companies, its shares are extremely sensitive to clinical trial results. The chart demonstrates how the company's stock can move completely independently of the market, reacting to unique scientific news.
Market capitalization of the company, segment and market as a whole
ACAD - Market capitalization of the company ACADIA Pharmaceuticals
This chart reflects the market capitalization of ACADIA Pharmaceuticals, which focuses on diseases of the central nervous system. Its volatile dynamics reflect investor reactions to clinical trial results and regulatory decisions regarding its drugs. The scale of the company's value reflects how the market perceives the potential of its drugs for treating complex neurological disorders.
ACAD - Share of the company's market capitalization ACADIA Pharmaceuticals within the market segment - Neuro
ACADIA Pharmaceuticals focuses on diseases of the central nervous system, occupying a significant market share in this complex niche. Its market capitalization reflects both the success of its already approved psychosis medications and investor expectations for future developments in neuroscience.
Market capitalization of the market segment - Neuro
Below is a chart reflecting the combined weighting of the entire neuroscience pharmaceutical sector—one of the most complex and risky in biotech. For ACADIA Pharmaceuticals, this line represents overall investor interest in brain disease treatments. Its rise and fall reflect waves of optimism or disappointment from clinical trials across the industry.
Market capitalization of all companies included in a broad market index - GURU.Markets
ACADIA Pharmaceuticals is focused on treating diseases of the central nervous system. Its market value represents the promise of a breakthrough in one of the most complex areas of medicine. It represents the share of global capital that investors are investing in the fight for brain health.
Book value capitalization of the company, segment and market as a whole
ACAD - Book value capitalization of the company ACADIA Pharmaceuticals
ACADIA Pharmaceuticals focuses on CNS diseases, and its book value is the material foundation for its research. It includes the value of laboratories, patents, and production equipment used to create innovative drugs. Has the company expanded its scientific and manufacturing foundation? The chart below shows this trend.
ACAD - Share of the company's book capitalization ACADIA Pharmaceuticals within the market segment - Neuro
ACADIA Pharmaceuticals focuses on CNS diseases, but its developments require a solid infrastructure. These include modern research centers, laboratories, and clinical trial equipment. The chart shows the company's share of the physical R&D infrastructure in the neuroscience segment of the pharmaceutical industry.
Market segment balance sheet capitalization - Neuro
ACADIA Pharmaceuticals is a biotechnology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. ACADIA focuses on diseases of the central nervous system, and its capital is primarily intellectual property, supported by an R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
ACADIA Pharmaceuticals focuses on the brain, but its business is firmly rooted in solid ground. The company's book value is derived from its research and development centers, laboratories, and capital supporting the development of new drugs. The chart shows the material foundation upon which innovation in the field of central nervous system disorders is built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ACADIA Pharmaceuticals
ACADIA's balance sheet is capital for research. But investors see it not as that, but as hope for new drugs for brain disorders. The chart shows the "hope multiplier": how much the market values a potential blockbuster in its portfolio higher than all of its current assets. This is a pure bet on scientific success.
Market to book capitalization ratio in a market segment - Neuro
ACADIA Pharmaceuticals is focused on developing drugs for the treatment of central nervous system disorders. Its value lies in its pipeline and research. This chart shows how much investor expectations for future sales and drug approvals exceed the value of its current tangible assets.
Market to book capitalization ratio for the market as a whole
ACADIA Pharmaceuticals is focused on developing drugs for the treatment of central nervous system diseases. The company's main assets are not its manufacturing facilities, but its research and development (R&D) and patent portfolio. This chart shows the overall market valuation, but how do investors view a biotech company whose success depends on clinical trial results?
Debts of the company, segment and market as a whole
ACAD - Company debts ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company with approved drugs. Unlike research-stage companies, it can use debt to finance the marketing of existing drugs and the development of new indications for their use. This strategy leverages current cash flows for future growth.
Market segment debts - Neuro
ACADIA Pharmaceuticals focuses on developing drugs for the treatment of central nervous system disorders, an area with long and expensive clinical trial cycles. This chart provides insight into how the company funds its research and development activities and how its financial structure is typical of the biotech industry.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ACADIA Pharmaceuticals
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of central nervous system diseases. This chart shows how the company finances its operations. For a biopharmaceutical company whose revenue depends on the success of several key drugs, debt management is a critical element of its financial strategy and development risk management.
Market segment debt to market segment book capitalization - Neuro
Developing drugs to treat nervous system diseases, ACADIA's focus, is a lengthy and expensive process. This chart illustrates how the biotech sector as a whole finances its research. It allows one to assess how ACADIA's debt load, with its specific drug portfolio, aligns with the overall financial strategy of this research-intensive industry.
Debt to book value of all companies in the market
This chart is a barometer of the entire economy's debt burden. ACADIA Pharmaceuticals, which develops drugs for the central nervous system, incurs enormous R&D costs without stable revenue. A comparison with the overall market shows how different the financial model of a biotech company, which thrives on investments in science, is from that of a traditional, profitable business.
P/E of the company, segment and market as a whole
P/E - ACADIA Pharmaceuticals
For ACADIA Pharmaceuticals, this chart shows investor sentiment toward its prospects in the treatment of CNS diseases. The high multiple, typical for biopharma, reflects expectations for the success of existing drugs and confidence in the potential of pipeline developments. This is an assessment of future blockbusters, not just current sales.
P/E of the market segment - Neuro
Pharmaceuticals, especially in the neuroscience field where ACADIA operates, require extensive research. This chart shows the average valuation for biopharmaceutical companies. It helps understand how investors assess the sales of ACADIA's already approved drugs and the risks associated with the development and approval of new drugs for CNS diseases.
P/E of the market as a whole
ACADIA Pharmaceuticals focuses on developing innovative drugs for the treatment of central nervous system (CNS) disorders, such as Parkinson's disease and psychosis. This chart reflects the overall risk appetite of investors in the biotech sector. It helps understand whether ACAD's valuation is based on confidence in the success of its specific drugs or whether it moves in line with overall industry sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ACADIA Pharmaceuticals
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of diseases of the central nervous system. This chart reflects investor expectations for the commercial success of existing drugs and the clinical trial results of new candidates. Its dynamics reflect the market's assessment of the scientific and commercial potential of the company's neuroscience pipeline.
%20P%2FE%20ACADIA%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ACADIA-Pharmaceuticals&v=1772513676179 "Chart of the company's future (projected) P/E ACADIA Pharmaceuticals")
Future (projected) P/E of the market segment - Neuro
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of central nervous system diseases, solving complex medical problems. This chart shows how analysts estimate its future revenue compared to other biopharmaceutical companies. Do these estimates reflect the prospects of its key drugs and research?
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772513676207 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
ACADIA Pharmaceuticals specializes in the treatment of diseases of the central nervous system. Like many biopharmaceutical companies, its value is determined by the success of its drugs on the market and in development. Amidst general market forecasts, ACADIA is driven by FDA news and clinical trial data, which are more important than the overall market situation.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513676221 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ACADIA Pharmaceuticals
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of central nervous system disorders. The company's financial performance depends on the market success of its key drugs and the R&D budget for new molecules. This chart shows how sales of existing drugs and progress in clinical trials shape its path from loss-making to potential profitability.
Profit of companies in the market segment - Neuro
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of central nervous system disorders. Its success depends on the results of clinical trials and the commercialization of its products. The chart presented here reflects the overall dynamics of the neuroscience sector, where unmet medical needs create enormous potential for growth.
Overall market profit
ACADIA Pharmaceuticals focuses on developing drugs for the treatment of central nervous system disorders. Like many biotech companies, its shares are dependent on research results. However, overall market sentiment, linked to corporate earnings trends, impacts the availability of capital for long-term R&D projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ACADIA Pharmaceuticals
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of central nervous system disorders, solving complex medical problems. The company's future depends on the success of its drugs and clinical trials. This chart represents the collective analyst consensus on the commercial potential of ACADIA's drug portfolio and its future profitability.
%20profit%20of%20the%20company%20ACADIA%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ACADIA-Pharmaceuticals&v=1772513676319 "Graph of future (projected) profit of the company ACADIA Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Neuro
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of central nervous system diseases. Its success depends on the results of clinical trials and the commercialization of its products. This chart shows profitability forecasts for the pharmaceutical sector, giving investors an understanding of the overall context in which ACADIA strives to bring its innovations to market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772513676331 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
ACADIA Pharmaceuticals is a biopharmaceutical company focused on diseases of the central nervous system. Its success is driven by research and development of new drugs. The company's business is independent of macroeconomic trends, as reflected in this market earnings forecast. The key drivers are science, innovation, and regulatory approval.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513676368 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ACADIA Pharmaceuticals
For ACADIA Pharmaceuticals, which focuses on neurological disorders, this chart visualizes investor confidence. The market capitalization-to-sales ratio of its key drugs demonstrates the market's confidence not only in its current products but also in the potential of its research and development for the future.
P/S market segment - Neuro
ACADIA Pharmaceuticals specializes in the development and commercialization of innovative drugs for the treatment of central nervous system diseases. This chart reflects the average revenue estimate for the neurological drugs sector. It helps understand how highly investors value the potential revenue from the company's current and future drugs in this complex therapeutic area.
P/S of the market as a whole
ACADIA Pharmaceuticals focuses on developing drugs to treat central nervous system disorders, such as Parkinson's disease-related psychosis. Their revenue depends on the success of one or more key drugs. This chart shows the overall market revenue estimate, providing context for understanding how investors assess the risks and potential of biotech companies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ACADIA Pharmaceuticals
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of central nervous system disorders. This chart illustrates how the market estimates the company's future revenue. This estimate depends largely on the commercial success of its current drugs and the results of clinical trials of new molecules targeting complex neurological diseases.
%20P%2FS%20ACADIA%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ACADIA-Pharmaceuticals&v=1772513676466 "The graph of the company's future (projected) P/S ACADIA Pharmaceuticals")
Future (projected) P/S of the market segment - Neuro
ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. Its success depends on the results of clinical trials and drug commercialization. This chart compares the company's expected future sales with those of the entire neuroscience biotechnology sector.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772513676505 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
ACADIA Pharmaceuticals specializes in the treatment of central nervous system disorders. The company's success depends on the approval and sales of its drugs. This schedule, reflecting overall economic optimism, influences the willingness of healthcare systems and insurance companies to cover the costs of new, often expensive, medications. Positive market expectations may facilitate wider adoption of ACADIA's drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513676574 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ACADIA Pharmaceuticals
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of central nervous system disorders. This chart shows the company's revenue, primarily from sales of its key drug for the treatment of Parkinson's disease psychosis. The growth here reflects successful market penetration and meeting a significant medical need for patients.
Sales of companies in the market segment - Neuro
ACADIA Pharmaceuticals specializes in developing innovative drugs for the treatment of central nervous system diseases. Its financial results are directly dependent on the success of specific drugs. This chart shows revenue for one of its key drug segments, allowing us to assess its commercial success and market penetration.
Overall market sales
ACADIA Pharmaceuticals specializes in treating diseases of the central nervous system. Its financial performance depends not on the state of the economy, but on the success of clinical trials and the approval of new drugs. The company works to solve complex medical problems, creating long-term value in the healthcare sector, which is a vital part of the modern economy.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system (CNS) disorders. The sales forecast reflects market expectations for the commercial success of its key drug for the treatment of Parkinson's disease psychosis and the potential of other CNS developments in its pipeline.
%20sales%20of%20the%20company%20ACADIA%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ACADIA-Pharmaceuticals&v=1772513676780 "Schedule of future (projected) sales of the company ACADIA Pharmaceuticals")
Future (projected) sales of companies in the market segment - Neuro
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of central nervous system disorders. This chart reflects revenue expectations for the pharmaceutical sector, focusing on neuroscience. It helps assess the commercial potential analysts see in new brain treatments, which is key to the company's valuation.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772513676809 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
ACADIA Pharmaceuticals focuses on diseases of the central nervous system. The company's success depends on healthcare budgets and patient affordability. This overall sales forecast chart reflects economic prosperity, which allows society and the government to allocate more funds for innovative medicines.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513676851 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ACADIA Pharmaceuticals
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of central nervous system diseases. Like many biopharmaceutical companies, its financial history is one of high research costs. This chart shows how revenue from approved drugs compares to development costs, determining the bottom line.
Market segment marginality - Neuro
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of central nervous system disorders. The company focuses on diseases with unmet medical needs. Profitability in this segment depends on the success of clinical trials and patent protection for its drugs. This chart provides an overview of the operational efficiency of their business model.
Market marginality as a whole
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of central nervous system diseases. The company's success depends on the results of clinical trials and the commercialization of its products. This graph reflects the profitability of mature companies, whereas for ACADIA, the key is the potential of its scientific developments and the future demand for innovative treatments.
Employees in the company, segment and market as a whole
Number of employees in the company ACADIA Pharmaceuticals
ACADIA Pharmaceuticals specializes in diseases of the central nervous system. This chart shows the growth of its scientific and commercial teams. The increase in headcount, particularly in the sales department, is a key indicator of success in launching and promoting its drugs for conditions such as Parkinson's disease psychosis.
Share of the company's employees ACADIA Pharmaceuticals within the market segment - Neuro
ACADIA Pharmaceuticals focuses on treating diseases of the central nervous system. Developing such complex drugs is a marathon, requiring a large and stable team of scientists. This metric reflects its significant presence in the neuroscience sector, demonstrating its commitment to long-term scientific research.
Number of employees in the market segment - Neuro
ACADIA Pharmaceuticals is focused on developing drugs for the treatment of central nervous system diseases. This chart shows employment in the neuroscience sector. The growing number of scientists and researchers in this field underscores the urgent need for new treatments and active investment in R&D, which underpins ACADIA's future growth and discoveries.
Number of employees in the market as a whole
ACADIA Pharmaceuticals specializes in diseases of the central nervous system. While demand for its medications is stable, the strong economy, reflected in this chart, ensures sustainable funding for the healthcare system and insurance programs. This ensures the affordability of high-priced, innovative medications for patients, which is critical to the company's success.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals specializes in treating diseases of the central nervous system. Like many biotech companies, its value is based on its intellectual property. The extremely high market capitalization per employee in this chart reflects the market's assessment of the potential of its drugs in development, not its current assets or headcount.
%20of%20the%20company%20ACADIA%20Pharmaceuticals%20(ACAD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ACADIA-Pharmaceuticals-ACAD&v=1772513677123 "Chart of market capitalization per employee (in thousands of dollars) of the company ACADIA Pharmaceuticals (ACAD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
ACADIA (ACAD) is a biopharmaceutical company focused on neuroscience (Parkinson's disease). Its value lies in R&D and patents. This chart shows the market capitalization per employee, which is a barometer of the market's confidence in the company's research productivity and future blockbusters.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772513677136 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of central nervous system diseases. Like any biotech company, its value is determined by the success of clinical trials and patents. This chart illustrates the high potential value the market attributes to the work of each scientist at the company.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513677149 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals specializes in diseases of the central nervous system (CNS). Their key drug, Nuplazid, is designed to treat psychosis associated with Parkinson's disease. In the pharmaceutical industry, profit per employee reflects the success of R&D and commercialization. This chart shows how effectively their research and marketing teams can market and sell their specialized drugs to a niche audience.
%20Chart%20ACADIA%20Pharmaceuticals%20(ACAD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ACADIA-Pharmaceuticals-ACAD&v=1772513677180 "Company Profit Per Employee (in thousands of dollars) Chart ACADIA Pharmaceuticals (ACAD)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
ACADIA is a biopharmaceutical company focused on neuroscience (blockbuster Nuplazid for Parkinson's psychosis). This chart shows the benchmark for "Neuro" (Biotech). In this R&D sector, the benchmark is either negative (at the R&D stage) or astronomically high. This is the "blockbuster business," where a single patent generates billions.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772513677300 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
ACADIA Pharmaceuticals (ACAD) is a biopharmaceutical company specializing in the development of treatments for central nervous system (CNS) disorders, particularly Parkinson's disease-related psychosis. This chart, showing average earnings per employee across the market, serves as a backdrop. It helps to assess the extent to which biotechnology, where a single successful drug can recoup years of R&D, is a high-margin industry.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513677319 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals is focused on developing drugs for the treatment of central nervous system diseases. This chart is an indicator of its commercial success. After a drug is launched, it shows how sales revenue compares to the size of the team, reflecting the effectiveness of its marketing strategy and the demand for its innovative treatments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ACADIA-Pharmaceuticals-ACAD&v=1772513677350 "Sales chart per company employee ACADIA Pharmaceuticals (ACAD)")
Sales per employee in the market segment - Neuro
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of central nervous system (CNS) disorders. Their key product is a drug for the treatment of psychosis associated with Parkinson's disease. This chart compares ACADIA's revenue per employee with the segment. It demonstrates how effectively their commercial team promotes drugs and how their R&D converts into revenue.
Sales per employee for the market as a whole
ACADIA Pharmaceuticals specializes in diseases of the central nervous system. Their key drug, Nuplazid, is approved for the treatment of psychosis associated with Parkinson's disease. Unlike R&D-stage biotechs, ACADIA is a commercial company with its own sales team. This chart shows how effectively their commercial and scientific structure generates actual drug sales.
Short shares by company, segment and market as a whole
Shares shorted by company ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals specializes in diseases of the central nervous system (CNS). Their success depends entirely on several key drugs. Investors closely monitor clinical trial results and regulatory decisions (e.g., the FDA). This chart shows the percentage of those who are skeptical of the success of current developments or fear generic competition.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ACADIA-Pharmaceuticals-ACAD&v=1772513677386 "Short Shares Chart for the Company ACADIA Pharmaceuticals (ACAD)")
Shares shorted by market segment - Neuro
ACADIA Pharmaceuticals specializes in diseases of the central nervous system (CNS). Their main success is a drug for the treatment of psychosis associated with Parkinson's disease. It is a risky biotech, dependent on R&D and patents. This chart shows the odds against the CNS biotech sector, reflecting the doubts about the success of future drugs.
Shares shorted by the overall market
ACADIA (ACAD) is a biopharmaceutical company (neurology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk. Biotech stocks, even those with stable drug revenues, often suffer sell-offs when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals focuses on drugs for the treatment of central nervous system diseases. Success depends on drug approval and sales. This chart for ACAD can soar above 70 on positive news from the FDA. A range below 30 is often associated with trial failures, delays, or competitive concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ACADIA-Pharmaceuticals-ACAD&v=1772513677459 "RSI 14 indicator chart for the company's stock ACADIA Pharmaceuticals (ACAD)")
RSI 14 Market Segment - Neuro
ACADIA (ACAD) is a biotech company focused on the brain. Their success is Nuplazid, the only drug for Parkinson's psychosis. Their challenge is finding a second hit. This chart shows the overall sentiment in the biotech sector. It helps us understand: is ACAD oversold due to an R&D failure or is there a general cooling off in the entire neurobiotech sector?
RSI 14 for the overall market
ACADIA Pharmaceuticals (ACAD) focuses on CNS diseases. As with many biotechs, this chart is a lifeline, indicating capital availability. In moments of euphoria, investors are willing to fund ACAD's long and risky clinical trials. When the market is in a panic, raising money for R&D that may not pay off becomes extremely difficult.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ACAD (ACADIA Pharmaceuticals)
ACADIA Pharmaceuticals specializes in developing drugs for the treatment of central nervous system (CNS) disorders. Their lead drug, Nuplazid, is approved for the treatment of psychosis associated with Parkinson's disease. This chart reflects analyst consensus based on Nuplazid sales forecasts and estimates of the potential of other drugs in development.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ACAD-ACADIA-Pharmaceuticals&v=1772513677552 "A chart showing analyst consensus forecasts for the expected stock price. ACAD (ACADIA Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price ACAD (ACADIA Pharmaceuticals)
ACADIA Pharmaceuticals (ACAD) is a biopharmaceutical company focused on treating central nervous system (CNS) disorders, including psychosis associated with Parkinson's disease. This chart is an R&D barometer. It measures the gap between the price and the consensus target, reflecting analyst confidence in the success of their drugs for complex neurological diseases.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ACAD-ACADIA-Pharmaceuticals&v=1772513677587 "A chart showing the difference between the consensus forecast and the actual stock price. ACAD (ACADIA Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Neuro
ACADIA Pharmaceuticals is a biotech company focused on treating central nervous system (CNS) disorders, such as schizophrenia and Parkinson's disease-related psychosis. This chart shows analysts' overall expectations for the entire neuroscience sector. It reflects whether experts believe breakthroughs in the treatment of complex brain diseases are possible.
Analysts' consensus forecast for the overall market share price
ACADIA Pharmaceuticals is a biopharmaceutical company specializing in diseases of the central nervous system (CNS). Their key drug is designed to treat psychosis associated with Parkinson's disease. This chart shows overall market sentiment. For ACADIA, whose success depends on sales of existing drugs and the success of new developments, overall market optimism is important, but regulatory news (like the FDA) carries more weight.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biotech company focused exclusively on diseases of the central nervous system (CNS). Their first success was Nuplazid, a drug for the treatment of psychosis associated with Parkinson's disease. This chart evaluates their niche focus. It reflects the commercial success of their current drug and, more importantly, the market valuation of their R&D pipeline in the complex field of neuroscience.
AKIMA Market Segment Index - Neuro
ACADIA is a biotech focused exclusively on CNS (central nervous system) disorders; the company has achieved success with Nuplazid (for Parkinson's-related psychosis) and is advancing R&D in neurology. This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does this narrow (CNS) focus differentiate ACADIA from the average pharma company?
The AKIM Index for the overall market
ACADIA is a biotech company focused on the central nervous system (CNS). Its success is built on treating neurological disorders (such as Parkinson's disease). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this defensive science-driven biotech company stacks up against the backdrop of overall economic trends.
